4.6 Review

SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement

Journal

LANCET GASTROENTEROLOGY & HEPATOLOGY
Volume 6, Issue 3, Pages 218-224

Publisher

ELSEVIER INC
DOI: 10.1016/S2468-1253(21)00024-8

Keywords

-

Funding

  1. NIHR Newcastle Biomedical Research Centre
  2. National Institute of Health Research (NIHR) Biomedical Research Centre based at Imperial College London and Imperial College Healthcare NHS Trust
  3. NIHR Academic Clinical Lectureship
  4. Imperial College London
  5. Freed Foundation
  6. MRC [G0902022] Funding Source: UKRI
  7. UKRI [MR/S034919/1] Funding Source: UKRI

Ask authors/readers for more resources

SARS-CoV-2 vaccination in patients with IBD is supported due to anticipated low risks, despite some concerns that protective immune responses may be diminished in certain patients. Further research is needed to address vaccine hesitancy, the impact of immunosuppression, and the search for predictive biomarkers of vaccine success.
SARS-CoV-2 has caused a global health crisis and mass vaccination programmes provide the best opportunity for controlling transmission and protecting populations. Despite the impressive clinical trial results of the BNT162b2 (Pfizer/BioNTech), ChAdOx1 nCoV-19 (Oxford/AstraZeneca), and mRNA-1273 (Moderna) vaccines, important unanswered questions remain, especially in patients with pre-existing conditions. In this position statement endorsed by the British Society of Gastroenterology Inflammatory Bowel Disease (IBD) section and IBD Clinical Research Group, we consider SARS-CoV-2 vaccination strategy in patients with IBD. The risks of SARS-CoV-2 vaccination are anticipated to be very low, and we strongly support SARS-CoV-2 vaccination in patients with IBD. Based on data from previous studies with other vaccines, there are conceptual concerns that protective immune responses to SARS-CoV-2 vaccination may be diminished in some patients with IBD, such as those taking anti-TNF drugs. However, the benefits of vaccination, even in patients treated with anti-TNF drugs, are likely to outweigh these theoretical concerns. Key areas for further research are discussed, including vaccine hesitancy and its effect in the IBD community, the effect of immunosuppression on vaccine efficacy, and the search for predictive biomarkers of vaccine success.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available